EGFR and KRAS mutation analyses from specimens obtained by bronchoscopy and EBUS-TBNA.

摘要: Backgroud Procurement of tumor tissue is mandatory for a mutation analysis in patients with non-small cell lung cancer. The purpose this study was to evaluate the usefulness bronchoscopic biopsy and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) detecting epidermal growth factor receptor (EGFR) KRAS mutations routine practice. Methods Tumor DNA extracted from formalin-fixed paraffin-embedded tissues, amplifications exons 18–21 EGFR codons 12, 13 61 were performed using polymerase chain reaction (PCR). PCR products subjected direct sequencing both directions. Results Of 211 consecutive specimens, 201 (95.3%) available analysis, 196 (92.9%) adequate analysis. detected 14.9% 5.4%, respectively. A median 16 days spent final report either or status. detection rates similar between EBUS-TBNA (P > 0.05). Female gender (53.3%), never smoker (63.3%), adenocarcinoma (96.7%) predominant mutations. Among (n = 104), frequencies 27.9% 10.6%, respectively. Conclusions Small samples obtained by are sufficient practice. Therefore, concurrent mutational analyses small should be considered at time initial diagnosis.